about
Structural Basis for the ABO Blood-Group Dependence of Plasmodium falciparum RosettingABCB6 is dispensable for erythropoiesis and specifies the new blood group system LangereisProof of principle for transfusion of in vitro-generated red blood cells.Live Brucella spp. fail to induce tumor necrosis factor alpha excretion upon infection of U937-derived phagocytes.Management of a pregnant woman with anti-holley alloantibody.Lack of the nucleoside transporter ENT1 results in the Augustine-null blood type and ectopic mineralization.Identification of the Molecular and Genetic Basis of PX2, a Glycosphingolipid Blood Group Antigen Lacking on Globoside-deficient Erythrocytes.Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system JuniorDisruption of SMIM1 causes the Vel- blood type.A review of the Colton blood group system.Banking of pluripotent adult stem cells as an unlimited source for red blood cell production: potential applications for alloimmunized patients and rare blood challenges.The LAN blood group system:a review.Characterization of a new human monoclonal antibody directed against the Vel antigen.A novel GYPB-A-B hybrid gene responsible for Ss and MN typing discrepancies.The French national rare blood program.The Vel blood group system: a review.Short duplication within the RHCE gene associated with an in cis deleted RHD causing a Rhnull amorph phenotype in an immunized pregnant woman with anti-Rh29.A functional AQP1 allele producing a Co(a-b-) phenotype revises and extends the Colton blood group system.Prevalence and risk factors for red blood cell alloimmunization in 175 children with sickle cell disease in a French university hospital reference centre.Enhanced calreticulin expression in red cells of polycythemia vera patients harboring the JAK2V617F mutation.Large deletions involving the regulatory upstream regions of A4GALT give rise to principally novel P1PK-null alleles.Family study of a Swiss patient uncovered a novel genetic basis for the S-s-U+(var) phenotype.Genetic background of the rare Yus and Gerbich blood group phenotypes: homologous regions of the GYPC gene contribute to deletion alleles.Band 3 phosphorylation induces irreversible alterations of stored red blood cells.Anti-HI can cause a severe delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease patients.[Difficulties of the care of public antigen alloimmunization].Anti-D investigations in individuals expressing weak D Type 1 or weak D Type 2: allo- or autoantibodies?Weak A phenotypes associated with novel ABO alleles carrying the A2-related 1061C deletion and various missense substitutions.Analysis of complement receptor type 1 expression on red blood cells in negative phenotypes of the Knops blood group system, according to CR1 gene allotype polymorphisms.Transfusion of rare cryopreserved red blood cell units stored at -80 degrees C: the French experience.Fatal hemolytic disease of the fetus and newborn associated with anti-Jr.[The rare blood groups: a public health challenge].Impact of hydroxycarbamide and interferon-α on red cell adhesion and membrane protein expression in polycythemia vera.The Gerbich blood group system: old knowledge, new importance.Alloanti-c/ce in a c+ceAR/Ce patient suggests that the rare RHCE ceAR allele (ceAR) encodes a partial c antigen.Severe autoimmune hemolytic anemia in a liver transplanted child[Quality control of labile blood products. Why and howto properly take a specimen? Labile Blood Products Group of the French Blood Transfusion Society][Transfusion safety, time for a new partnership between stake-holders]Donors with a rare pheno (geno) type[Genotyping of blood group systems at the CNRGS. I: FY, JK, MNS systems]
P50
Q27670781-AD2FC16D-5F0C-44AE-B685-BD4391B0FAC7Q28257493-B32C7DDC-B4CE-4B3D-BBA9-E40A9E352AC7Q34212764-43EBD3D8-4A01-4489-A0C2-6870F82A5D4FQ34546937-B2C25761-C6E4-40B8-8808-F7F9C52BE781Q35631259-B49D582C-90F1-4EAB-8CD4-F43709A9B54CQ35692423-0F698787-7DED-4D74-9DF6-939B121C2160Q35883826-86AE793A-AB91-4154-8915-DA20D65D0AC8Q36843054-819B7454-F652-45D4-8A71-E079F848BB24Q36870116-19A64B2B-DDE2-4EA3-96A1-0DB953790FEFQ37783239-E05B9458-F99E-4448-8D7C-40F4A025A74AQ37850066-C26F5402-9776-4ACA-8E9B-8E3216FD5C19Q38201115-25D30F5B-D681-4ED7-B079-55F30CCCB89BQ38834509-4ABB7D2C-DB3B-452A-A06A-DC49EA2E02B6Q38977075-FD89ABBA-E2FA-442C-97B5-4D34DBCE056DQ39011937-A9D69484-6068-4260-8A09-31F400310FA4Q39402390-918E5A0E-4325-4FDA-AB8E-C082C66E5C97Q39463994-87D53702-07EC-4085-A102-D88D1214637AQ39701491-1A5F3DA4-B340-4967-A4EE-77AB2B356A3FQ40246340-39B5DE4C-6FA3-4C2B-8564-55B4E5243F32Q42348456-16F856A0-B5F5-4413-939C-E8346403D891Q42637360-626C806F-D875-459D-881E-22C8458037A9Q46199373-3F59468F-598A-451B-9DA0-C73FBBFF62DEQ46718655-2FC951AF-E5D0-4E56-9D76-AB6DECD57D51Q48202500-C6B14EE7-0851-46DD-97AA-3A42A9EE8C98Q50241611-928BB13A-D711-4938-B76A-5FFB56E5781DQ50264643-9ECF5B08-2AFF-48E9-B7C0-71E107E8AF2DQ50533012-11CEAD89-436A-417C-B131-BF8BF2A43975Q50578077-FAA674D1-B356-498F-950A-6A009631062AQ50583480-091FA0D4-0A63-4098-B3C4-5B94A2A320A3Q50594482-35BC0EC7-E8B7-427F-BA44-4E868A512760Q50647011-F316862D-750F-4CDF-9F86-1CDD9FA254A6Q50653109-074414E2-C53D-402B-B110-78C4B39B7156Q52620954-5D953A43-D1AC-415D-B8C4-7086F27ECF39Q52655600-BB80B0AD-18E5-4C79-8348-424C3321A9A1Q54472381-ACBBB818-6CF8-4640-ADB7-752AFF1260C7Q63244977-61C055B1-0D27-45B4-9AE5-FB70C34AA771Q73428216-8919E0E8-8B8D-49A4-A0EE-630E8B4502BAQ79695976-848C28FE-A059-4884-B21A-C9A6E5B5729AQ83142416-CCEE4073-A66F-40B0-93D2-A5A74CACF6DEQ83704620-8AF989A3-72E9-4E12-B4B2-C42F80B4DA30
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Thierry Peyrard
@ast
Thierry Peyrard
@en
Thierry Peyrard
@es
Thierry Peyrard
@nl
type
label
Thierry Peyrard
@ast
Thierry Peyrard
@en
Thierry Peyrard
@es
Thierry Peyrard
@nl
prefLabel
Thierry Peyrard
@ast
Thierry Peyrard
@en
Thierry Peyrard
@es
Thierry Peyrard
@nl
P106
P31
P496
0000-0002-7715-568X